Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats

被引:12
|
作者
Zhang, RY
Wang, LF [1 ]
Zhang, L
Meng, XN
Li, SJ
Wang, WR
机构
[1] Harbin Med Coll, Clin Hosp 1, Dept Cardiol, Harbin 150001, Peoples R China
[2] Harbin Med Coll, Clin Hosp 1, Dept Pathol, Harbin 150001, Peoples R China
关键词
Smad; ventricular remodeling; angiotensin converting enzyme inhibitor; angiotensin II type I receptor blocker;
D O I
10.1097/00029330-200604020-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Transforming growth factor (TGF) beta(1)-Smads signal plays an important role in cardiac remodeling following myocardial infarction (MI). In addition, both angiotensin converting enzyme inhibitor (ACEI) and angiotensin II type I receptor blocker (ARB) can effectively prevent left ventricular remodeling. The current study focused on whether the combination of ACEI and ARB is more beneficial for preventing ventricular remodeling and whether Smad proteins mediate this beneficial effect. Methods MI was induced by ligating the left anterior descending coronary artery in rats. Twenty-four hours after ligation, the survived rats were randomly divided into five groups and treated for 8 weeks: placebo group, ACEI group (benazepril 10 mg (.) kg(-1) (.) d(-1)), ARB group (irbesartan 50 mg (.) kg-(1 .) d(-1)), ACEI + ARB group (benazepril 10 mg (.) kg (.) d(-1) + irbesartan 50 mg (.) kg (.) d(-1)) and control group (sham-operated rats). After 8 weeks, we examined the following indexes: the ratio of ventricular weight to body weight,(VW/BW), left ventricular end diastolic dimension (LVDd), ejection fraction (EF), fractional shortening (FS), ratio of E-wave to A-wave velocity, collagen of noninfarcted zone, the mRNA expression of TGF beta(1), Smad 2, and Smad 3 by RT-PCR in noninfarcted zone, the protein expression of Smad 2 and Smad 3 in noninfarcted zone by Western blot. Results VW/BW significantly increased in the placebo groups compared with that in the control group (P < 0.01). This increase was limited in ACEI, ARB, and combined groups (P < 0.01 compared with placebo group). There was no significant difference among the three actively treated groups. Collagen was increased in placebo group (5.68 +/- 0.5)% compared with that in control group (P < 0.01). ACEI, ARB and combined treatment attenuated this increase of collagen [(4.3 +/- 0.5)%, (3.5 +/- 0.5)%, (3.2 +/- 0.4)%] in comparison with that in placebo group (P < 0.01 respectively). Combined treatment showed more significant effect on collagen deposition. EF and FS significantly decreased, LVDd and E/A significantly increased in placebo group compared with that in control group (P < 0.01 respectively). ACEI, ARB and combined treatment ameliorated these indexes (P < 0.01 compared with placebo group). The mRNA expression of TGF beta(1), Smad 2, and Smad 3 (0.700 +/- 0.045, 0.959 +/- 0.037 and 0.850 +/- 0.051) increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective in decreasing TGF beta(1) and Smad mRNA expression than ACEI treatment (P < 0.01). The expression of Smad 2 and Smad 3 protein increased in placebo group compared with that in control group (P < 0.01). ACEI, ARB and combined treatment normalized the increase (P < 0.01). Furthermore, ARB and combined treatment proved to be more effective than ACEI alone (P < 0.01). Conclusions TGF beta(1)-Smads signal activation is correlated with ventricular remodeling following MI. ACEI and ARB treatment prevents ventricular remodeling by inhibiting expression of Smad 2 and Smad 3.. ARB and combined treatment are more effective than ACEI alone.
引用
收藏
页码:649 / 655
页数:7
相关论文
共 50 条
  • [21] Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease
    Toto, Robert
    Palmer, Biff F.
    AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (03) : 372 - 380
  • [22] Effects of a new angiotensin-converting enzyme inhibitor (idrapril) in rats with left ventricular dysfunction after myocardial infarction
    Jeremic, G
    Masson, S
    Luvara, G
    Porzio, S
    Lagrasta, C
    Riva, E
    Olivetti, G
    Latini, R
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (03) : 347 - 354
  • [23] Prevention of major cardiovascular events with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker early or late after stroke
    Van Mieghem, Walter
    JOURNAL OF HYPERTENSION, 2009, 27 : S26 - S31
  • [24] Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium
    Lenz, O
    Schmid, B
    Kilter, H
    LaRosee, K
    Flesch, M
    KuhnRegnier, F
    Sudkamp, M
    Bohm, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 294 (01) : 17 - 27
  • [25] High dietary sodium blunts effects of angiotensin-converting enzyme inhibition on vascular angiotensin I-to-angiotensin II conversion in rats
    Kocks, MJA
    Buikema, H
    Gschwend, S
    Boomsma, F
    de Zeeuw, D
    Navis, G
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 (05) : 601 - 606
  • [26] Additional salutary effects of the combination of exercise training and an angiotensin-converting enzyme inhibitor on the left ventricular function of spontaneously hypertensive rats
    Ziada, Amal M.
    JOURNAL OF HYPERTENSION, 2009, 27 (06) : 1309 - 1316
  • [27] Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: Addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker
    Furumatsu, Yoshiyuki
    Nagasawa, Yasuyuki
    Tomida, Kodo
    Mikami, Satoshi
    Kaneko, Tetsuya
    Okada, Noriyuki
    Tsubakihara, Yoshiharu
    Imai, Enyu
    Shoji, Tatsuya
    HYPERTENSION RESEARCH, 2008, 31 (01) : 59 - 67
  • [28] Effect of angiotensin II type 1 receptor blocker and angiotensin converting enzyme inhibitor on the intraocular growth factors and their receptors in streptozotocin-induced diabetic rats
    Byon, Ik Soo
    Lee, Dong Hyun
    Jun, Eun Sook
    Shin, Min Kyu
    Park, Sung Who
    Lee, Ji Eun
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (06) : 896 - 901
  • [29] Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker
    Yoshiyuki Furumatsu
    Yasuyuki Nagasawa
    Kodo Tomida
    Satoshi Mikami
    Tetsuya Kaneko
    Noriyuki Okada
    Yoshiharu Tsubakihara
    Enyu Imai
    Tatsuya Shoji
    Hypertension Research, 2008, 31 : 59 - 67
  • [30] Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure
    Mizukami, M
    Hasegawa, H
    Kohro, T
    Toko, H
    Kudoh, T
    Zou, YZ
    Aburatani, H
    Komuro, I
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 42 : S1 - S6